Recipharm
Global CDMO for pharmaceuticals
- B2B
- Has physical offices
- Manufacturing
- Sales-led purchase
About Recipharm
Experienced global CDMO offering full-service pharmaceutical development and manufacturing, with a focus on operational excellence, scientific expertise, and customer connectivity
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001–5,000 employees
- Headquarters
- Stockholm, Stockholm County, Sweden
- Founded
- 1995
- Revenue
- $137M – $1.1BTamtam estimate
- Website
- recipharm.com
- linkedin.com/company/recipharm
Recipharm in the news
- Recipharm förlänger avtalet med BIAL kring opicapone
Recipharm extends its manufacturing contract with BIAL for the Parkinson's drug Ongentys, which is now approved in several major markets including Japan.
- Recipharm får ytterligare stöd från Gates Foundation
Recipharm secures further funding from the Gates Foundation to advance AI-driven next-generation vaccine manufacturing.
- Recipharm secures grant to develop AI-enabled manufacturing technology
Recipharm obtained funding to develop AI-driven tools to improve pharmaceutical manufacturing speed, cost, and efficiency.
- Recipharms AI-satsning får stöd från Gates-stiftelse
Recipharm's Advanced Bio division secures Gates Foundation funding to advance AI and PAT technologies aimed at improving global medicine access.
Recipharm at a glance
Recipharm is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Stockholm, Stockholm County, Sweden.
Recipharm was founded in 1995.
Recipharm has 1,001–5,000 employees.
Recipharm's revenue is $137M – $1.1B (Tamtam estimate).
Selling to companies like Recipharm?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies